详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The Role of CD276 in Cancers.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. [2]William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. [3]Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. [4]Clinical Science and Services, Royal Veterinary College, University of London, London, United Kingdom.

出处：

DOI：

ISSN：

关键词： CD276 B7-H3 therapeutic target tumor progression

摘要：

Aberrant expression of the immune checkpoint molecule, CD276, also known as B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe the role of CD276 in malignancies and its potential therapeutic effect. Database including PubMed, EMbase, Cochrane Library, CNKI, and Clinical Trails.gov were searched for eligible studies and reviews. Study selection: Original studies and review articles on the topic of CD276 in tumors were retrieved. CD276 is an immune checkpoint molecule in the epithelial mesenchymal transition (EMT) pathway. In this review, we evaluated the available evidence on the expression and regulation of CD276. We also assessed the role of CD276 within the immune micro-environment, effect on tumor progression, and the potential therapeutic effect of CD276 targeted therapy for malignancies. CD276 plays an essential role in cell proliferation, invasion, and migration in malignancies. Results from most recent studies indicate CD276 could be a promising therapeutic target for malignant tumors. Copyright © 2021 Liu, Liang, Liu, Zhang, Wang, Watson, Zhou, Zhang, Wu, Zhang, Lu and Wang.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. [2]William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma [2]Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. [3]Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration [4]CD25: A potential tumor therapeutic target [5]Role of NSD1 as potential therapeutic target in tumor. [6]Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α. [7]AGRN promotes lung adenocarcinoma progression by activating Notch signaling pathway and acts as a therapeutic target [8]Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy [9]Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma [10]Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)